GNPX — Genprex Income Statement
0.000.00%
Last trade - 00:00- $7.00m
- $5.40m
Annual income statement for Genprex, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 18 | 20.7 | 23.8 | 31.1 | 21.2 |
| Operating Profit | -18 | -20.7 | -23.8 | -31.1 | -21.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.9 | -20.7 | -23.7 | -30.9 | -21.1 |
| Net Income After Taxes | -17.9 | -20.7 | -23.7 | -30.9 | -21.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.9 | -20.7 | -23.7 | -30.9 | -21.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.9 | -20.7 | -23.7 | -30.9 | -21.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -20.2 | -17.6 | -19.8 | -22.6 | -5.34 |